---
title: "Curanex Pharmaceuticals files draft information statement (Form PRE 14C)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290247521.md"
description: "Curanex Pharmaceuticals filed a draft information statement (Form PRE 14C) regarding shareholder approvals. Shareholders authorized a reverse stock split with a ratio between 1-for-10 and 1-for-50, to be determined by the board to increase per-share price. Additionally, they approved a 2026 equity incentive plan reserving up to 5.7 million shares for awards, including an annual reserve increase of up to 4% of outstanding shares."
datetime: "2026-06-18T21:12:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290247521.md)
  - [en](https://longbridge.com/en/news/290247521.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290247521.md)
generator: "portal-rs"
---

# Curanex Pharmaceuticals files draft information statement (Form PRE 14C)

-   Curanex shareholders authorized a reverse stock split of common stock, with the ratio set within a 1-for-10 to 1-for-50 range. \* The board would select the final split ratio, with the move aimed at lifting the per-share trading price. \* Shareholders also authorized a 2026 equity incentive plan reserving up to 5,700,000 common shares for awards to employees, directors, consultants. \* The plan includes an annual share reserve increase of up to 4% of outstanding shares, subject to administrator discretion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029388), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CURX.US](https://longbridge.com/en/quote/CURX.US.md)

## Related News & Research

- [Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295957896.md)
- [NewGenIvf’s Lee Sze Mun, director, files initial beneficial ownership statement](https://longbridge.com/en/news/296471529.md)
- [Medalist Diversified terminates deals to buy two Texas Caliber Collision Center properties](https://longbridge.com/en/news/296531150.md)
- [Lifeward names Avraham Gabay board chair after director Nadav Kidron steps down](https://longbridge.com/en/news/296531145.md)
- [10:41 ETDeepCura Unveils the Electronic Health Workforce (EHW) -- the Step Beyond the EHR](https://longbridge.com/en/news/296803806.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**